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ABSTRACT (288 words) 55 
Laboratory tests can play an important role in assessment of alcoholic patients, including for 56 
evaluation of liver damage and as markers of alcohol intake. Evidence on test performance 57 
should lead to better selection of appropriate tests and improved interpretation of results. We 58 
compared laboratory test results from 1578 patients between cases (with alcoholic cirrhosis; 59 
753 men, 243 women) and controls (with equivalent lifetime alcohol intake but no liver 60 
disease; 439 men, 143 women). Comparisons were also made between 631 cases who had 61 
reportedly been abstinent from alcohol for over 60 days and 364 who had not. ROC curve 62 
analysis was used to estimate and compare tests’ ability to distinguish patients with and 63 
without cirrhosis, and abstinent and drinking cases. The best tests for presence of cirrhosis 64 
were INR and bilirubin, with AUCs of 0.91 ± 0.01 and 0.88 ± 0.01 respectively. Confining 65 
analysis to patients with no current or previous ascites gave AUCs of 0.88 ± 0.01 for INR and 66 
0.85 ± 0.01 for bilirubin. GGT and AST showed discrimination between abstinence and 67 
recent drinking in patients with cirrhosis, including those without ascites, when appropriate 68 
(and for GGT, sex-specific) limits were used. For AST, a cut-off limit of 85 units/l gave 90% 69 
specificity and 37% sensitivity; for GGT cut-off limits of 288 units/l in men and 138 units/l in 70 
women gave 90% specificity for both and 40% sensitivity in men, 63% sensitivity in women. 71 
INR and bilirubin show the best separation between patients with alcoholic cirrhosis (with or 72 
without ascites) and control patients with similar lifetime alcohol exposure.  Although AST 73 
and GGT are substantially increased by liver disease, they can give useful information on 74 
recent alcohol intake in patients with alcoholic cirrhosis when appropriate cut-off limits are 75 
used. 76 
KEY WORDS 77 
Alcohol; cirrhosis; abstinence; aspartate aminotransferase; gamma glutamyl transferase. 78 
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BACKGROUND 79 
Laboratory tests play an important role in the diagnosis and monitoring of patients with 80 
alcoholic cirrhosis, both for assessing the degree of impairment of liver function by cirrhosis 81 
and for detecting ongoing alcohol intake. It is important to share information on test 82 
performance, to optimise test selection and diagnostic accuracy. 83 
Many aspects of liver function are impaired in cirrhosis, and form the basis of diagnostic or 84 
prognostic tests. These include excretory, synthetic, and metabolic functions, reflected in 85 
abnormal results for bilirubin; albumin and clotting factors; and glucose and ammonia, 86 
respectively. Damage to liver cells, perhaps combined with increased enzyme expression, 87 
leads to increases in plasma or serum activity of ‘liver enzymes’ (gamma-glutamyl 88 
transferase, GGT; aspartate aminotransferase, AST; alanine aminotransferase, ALT). 89 
Although it is recognised that quite advanced cirrhosis may occur with normal liver function 90 
test results (1-3), and there are recent papers comparing test results in drinking versus 91 
abstinent alcoholics (4) and in ‘heavy-drinking controls’ versus patients with alcoholic 92 
hepatitis (5) there is little published evidence on the comparative performance of widely 93 
available tests in distinguishing between the presence or absence of cirrhosis in heavy alcohol 94 
drinkers. Such evidence would be valuable in its own right, and because novel tests or 95 
algorithms  should be judged against the performance of currently available tests. 96 
A related issue is the value of biochemical tests as markers of alcohol use in patients with 97 
liver disease, particularly alcoholic liver disease. Because the prognosis in alcoholic cirrhosis 98 
is greatly improved by abstinence  and treatment decisions may be affected, objective and 99 
reliable measures of patients’ alcohol use can be helpful. Measurement of ethanol metabolites 100 
shows promise (6-8) but most either require frequent testing because of short half-lives (ethyl 101 
glucuronide and ethyl sulphate in urine) or are not widely available (ethyl glucuronide or 102 
fatty acid ethyl esters in hair, phosphatidylethanol in blood cell membranes). There are mixed 103 
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reports on whether serum disialotransferrin (carbohydrate-deficient transferrin, CDT) is 104 
affected by liver disease (9-14). A number of technical issues, depending on the method used, 105 
can affect the validity of CDT results in cirrhosis (15-17). Serum GGT, which is cheap and 106 
widely available, is a rather non-specific marker of liver damage as well as an index of 107 
alcohol intake , and it is increased in a high proportion of people with liver disease. GGT has 108 
therefore been discounted for this situation, though there is little information on its potential 109 
as an alcohol biomarker in the presence of liver disease. Nor is information readily available 110 
about the ability of other commonly available tests to distinguish abstinent from non-111 
abstinent patients. 112 
We have collected blood samples and clinical information, including alcohol intake history 113 
and laboratory test results, from 1578 patients either with liver cirrhosis due to alcohol or 114 
with similar alcohol intake but no history or symptoms of liver disease (18). These data allow 115 
us to address the two questions outlined above. First, which tests (including biochemical liver 116 
function tests, and haematology tests affected by cirrhosis) are best at distinguishing between 117 
those who do or do not have cirrhosis as a result of long-term excessive alcohol intake? 118 
Second, can any of these commonly available tests assist in identifying continuing alcohol 119 
use among patients with alcoholic liver disease?  120 
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METHODS 121 
Information was gathered from patients recruited for the GenomALC Study (18) up to the 122 
end of April 2016. Recruitment occurred in Australia, France, Germany, Switzerland, UK 123 
and USA, mainly from hepatology clinics (for cases, as defined below) and from psychiatric 124 
or detoxification facilities for the controls. All participants gave informed consent and the 125 
study was approved by appropriate Research Ethics Committees.  126 
To be eligible, participants had to have high-risk alcohol intake (greater than 80 grams per 127 
day for men, or 50 grams per day for women) for 10 years or more. Cases had alcohol-related 128 
cirrhosis, with the diagnosis based on one or more of the following clinical, histological or 129 
FibroScan criteria as reported (18) and detailed here. Clinical cirrhosis required documented 130 
evidence of one or more of the following: clinically detectable ascites (confirmed by imaging 131 
or by paracentesis); spontaneous hepatic encephalopathy (grade 2 or higher); moderate or 132 
large oesophageal varices on upper endoscopy. Histological cirrhosis required Metavir 133 
fibrosis stage F4 or Ishak fibrosis stage 5 or 6. Fibroscan diagnosis required an adequately 134 
performed FibroScan with F4 stiffness; the cut off was ≥22 kPa (if AST <100 IU/L within 2 135 
weeks of FibroScan), or ≥30 kPa (if AST between 100-200 IU/L within 2 weeks of 136 
FibroScan). Exclusion criteria included liver transplantation for liver disease other than 137 
alcoholic cirrhosis; hepatitis B or C (by hepatitis C antibody and hepatitis B surface antigen 138 
tests), known HIV, hemochromatosis (by transferrin saturation > 45% or 2+ iron on liver 139 
biopsy if performed), Wilson’s disease (by ceruloplasmin) or autoimmune hepatitis (by ANA 140 
titre).  141 
Control subjects had to meet the alcohol intake criteria with no history or current evidence of 142 
liver disease (history of jaundice, ascites, variceal bleeding, upper gastrointestinal bleeding of 143 
uncertain etiology, or blood tests which suggest impaired liver function or acute/chronic 144 
alcoholic liver injury). 145 
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Characteristics of 1578 participants who met the eligibility criteria are summarised in Table 146 
1. 147 
Lifetime alcohol intake estimates were based on participants’ recall of habitual daily use of 148 
beer, wine, spirits or other alcoholic beverages (converted to grams of alcohol), and of the 149 
number of years of high-risk drinking. Current abstinence was assessed by whether the 150 
patient reported they had been abstinent from alcohol for 60 days or more before recruitment. 151 
Data collection was planned before test and reference standard data were collected. 152 
Laboratory test results, as listed in Table 2, were gathered from those done for clinical 153 
reasons at the time of recruitment or performed for this study where necessary. We also 154 
calculated AST/ALT and AST/platelet ratios. MELD scores were calculated from INR, 155 
bilirubin and creatinine results (19) using the formula MELD = 3.78[Ln serum bilirubin 156 
(mg/dL)] + 11.2[Ln INR] + 9.57[Ln serum creatinine (mg/dL)] + 6.43. Results for bilirubin, 157 
INR and creatinine of less than 1.0 (in their respective units) were taken as 1.0, and results for 158 
creatinine of greater than 4.0 were taken as 4.0, as recommended by the United Network for 159 
Organ Sharing (UNOS) (https://www.unos.org/wp-160 
content/uploads/unos/MELD_PELD_Calculator_Documentation.pdf, accessed 2016-05-30).  161 
For comparison of means between groups, test results showing positively skewed 162 
distributions (bilirubin, creatinine, ALT, AST and GGT) were log10-transformed. For ROC 163 
curve analysis, test results where the case mean was lower than the control mean 164 
(hemoglobin; white cell count; platelet count; albumin) had the assumption of higher results 165 
indicating abnormality reversed so that areas under the ROC curve (AUC) were greater than 166 
0.5. Statistical analyses were performed using SPSS (IBM Corporation, Armonk, New York 167 
10504). 168 
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RESULTS 169 
The test means for abstinent and non-abstinent cases and controls are summarised in Table 2, 170 
with results for men and women shown separately in Supplementary Table 1. P-values for 171 
both the effects of presence of cirrhosis and of abstinence on the means, and for case/control 172 
by abstinent/non-abstinent interaction, are also shown. Most of the tests showed differences 173 
between the case and control groups, but only AST and GGT showed significant effects of 174 
abstinence. These two tests also showed significant case/control by abstinent/non-abstinent 175 
interaction terms. Plots for AST and GGT by case-control status and by abstinence, to 176 
illustrate the main effects and interaction, are shown in Figure 1; reported abstinence was 177 
associated with lower AST and GGT in cases but not in controls (but very few control 178 
patients had abstained from alcohol). 179 
The ability of the laboratory tests to distinguish cases from controls is summarised in Table 3. 180 
ROC curves (which plot test sensitivity, true positive rate, against (1-specficity), false 181 
positive rate) are shown for the most discriminating tests (hemoglobin, platelet count, INR, 182 
bilirubin and albumin) and the MELD score in Supplementary Figure 1. Because there is 183 
always a trade-off between better sensitivity and better specificity, determined by the chosen 184 
cut-off value separating ‘normal’ from ‘abnormal’ results, comparisons of sensitivity between 185 
tests or between groups of patients should be based on the same specificity for each. For our 186 
comparisons, we have chosen 90% specificity (10% false positive rate) unless otherwise 187 
noted, and report the cut-off values and sensitivities associated with that specificity. 188 
Most (77%) of the patients with alcoholic cirrhosis had current or prior ascites. In order to 189 
test how far this affected the test results and their diagnostic performance, we conducted 190 
further analyses on case sub-groups defined by presence or history of ascites, comparing 191 
those with and without ascites. For most tests, ascites was significantly associated with more-192 
abnormal results (Supplementary Table 2), and exclusion of cases with reported ascites 193 
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decreased the case-control AUCs (Table 4). The notable exceptions were AST and GGT, 194 
where ascites was associated with lower (less abnormal) mean values and with higher AUCs. 195 
Because only 17 of the controls reported abstinence for 60 days preceding recruitment, 196 
analysis of the ability of tests to distinguish abstinence from continued drinking was confined 197 
to the cases (Table 3). The only tests showing AUC above 0.70 were AST and GGT, and 198 
results for these are shown in more detail in Table 5 and Figure 2. When data from men and 199 
women were analysed together, the AUC for AST was 0.737 and for GGT 0.771. This 200 
analysis was then repeated for male and female cases separately (also shown in Table 5). For 201 
AST, the AUC, test sensitivities and cut-off values were similar in men and women; but for 202 
GGT the AUC was greater in women than in men and the appropriate cut-off values 203 
(determined by the desired specificity) were substantially higher in men. 204 
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DISCUSSION 205 
We have compared the performance of routine tests, and the composite MELD score, for 206 
distinguishing between patients with alcoholic cirrhosis (cases) and patients with similar 207 
lifetime exposure to alcohol but no liver disease (controls). The best of these tests show good 208 
discrimination, consistent with the comparison of selected groups and with clinical 209 
experience. We have also compared results from abstinent and non-abstinent patients with 210 
alcoholic cirrhosis. The tests which perform best for making the distinction between abstinent 211 
and non-abstinent cases are GGT and AST and they perform well in patients with advanced 212 
liver disease as long as appropriately high cut-off limits are used.  213 
It is generally accepted that conventional liver function tests have poor sensitivity in 214 
detecting cirrhosis, particularly in the early stages. Although our cases have (or have had) 215 
clinical symptoms, and we accept that we are comparing selected extremes of the spectrum of 216 
potential patients, we find that INR, bilirubin, platelet count and albumin – in that order - 217 
give good discrimination between cases and controls (Table 3). The best single test, INR, had 218 
an AUC of 0.914 and test sensitivity of 78% at a specificity of 90%. Even in less advanced 219 
disease, i.e. after restricting the analyses to patients without ascites, INR and bilirubin 220 
continued to show good separation between the case and control groups.  221 
The calculated AST/ALT ratio showed better discrimination than either of its components in 222 
the case/control comparison (see Table 3). The AST/platelet ratio showed no advantages, 223 
being significantly worse than platelet count for case/control discrimination or AST for 224 
drinking/abstinence (again, see Table 3); this is consistent with a previous evaluation (20). 225 
The MELD score, being based on INR, bilirubin and creatinine, gives results equivalent to 226 
(but no better than) the INR measurement alone for the case versus control comparison 227 
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(although MELD may still be superior to any single test for other purposes, such as 228 
prognosis, which we did not evaluate).  229 
To be an improvement on what is already available, any new test or test combination would 230 
need to achieve either an AUC above 0.91 in patients equivalent to ours, or an equal 231 
sensitivity and specificity in patients with less advanced disease. Indicators of fibrosis might 232 
be valuable in patients with less advanced disease, and a number have been investigated. 233 
Results were summarised in (3), with some markers having high reported AUCs or promising 234 
sensitivity and specificity values in comparatively small studies. A direct comparison of three 235 
fibrosis markers, tissue inhibitor of metalloproteinase 1, aminoterminal propeptide of type III 236 
collagen and hyaluronic acid , showed highly significant differences in mean values between 237 
alcoholic patients with mild and advanced fibrosis but the AUCs were in the range 0.67-0.69 238 
and sensitivity was around 33% at 90% specificity. 239 
Another important clinical question is whether people with known alcoholic cirrhosis are 240 
abstaining from alcohol. Taking the cases only, ROC curve analysis was performed to assess 241 
the ability of the laboratory tests to classify people as abstinent or non-abstinent (Tables 3 242 
and 5, Figure 2). The tests which were best at distinguishing cases from controls (INR, 243 
bilirubin, platelet count, albumin) performed poorly in distinguishing abstinent and non-244 
abstinent cases; they are detecting cirrhosis rather than drinking. It is unexpected that test 245 
results are not closer to normal in the abstinent than in the drinking cases, although the period 246 
of abstinence specified (60 days or more) may be too short to have made a difference.  247 
On the other hand, AST and GGT, which did not perform well for the case-control 248 
comparison, did surprisingly well in the abstinent-drinking comparison. These are tests which 249 
are primarily measuring liver cell damage and/or enzyme induction and which have not 250 
previously been considered useful in the presence of liver disease. In fact, the test 251 
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performance (Table 5) for GGT is very similar to that derived from meta-analysis of data 252 
from studies on people without liver disease (21) (which estimated GGT sensitivity of 44% 253 
and AST sensitivity of 27%, each at 90% specificity). However, the GGT value giving this 254 
specificity and sensitivity in our cases (about 250 units/l) is much higher than it would be in 255 
alcoholics without known liver disease. 256 
Another point to notice is that AST and GGT performed slightly better, both in the case-257 
control and abstinent-drinking comparisons, in patients with cirrhosis but no ascites (Table 258 
4). This is in contrast to the other tests, and is probably due to decreased liver cell mass in the 259 
patients with more advanced disease who have or have had ascites. As these enzymes 260 
originate from the liver, very low functioning liver cell mass will lead to less enzyme release 261 
into the circulation. 262 
For the evaluation of abstinence in individuals with cirrhosis, we found relevant differences 263 
in test performance between men and women. The performance of GGT was better in women 264 
than in men (Table 5, Figure 2) and the appropriate cut-off values for various levels of 265 
specificity were higher in men. For example, a cut-off value of around 290 units/l would give 266 
40% sensitivity and 90% specificity in men but a cut-off value of 140 units/l would give 63% 267 
sensitivity and 90% specificity in women. (The cut-off value for equivalent specificity in the 268 
absence of liver disease would be around 40-50 units/l.) On the other hand, AST (which 269 
performs about as well as GGT as an alcohol marker in the alcoholic cirrhosis context) 270 
showed similar test performance and cut-off limits in men and women (Table 5), with a cut-271 
off of around 85 units/l (still substantially above the appropriate value for people without 272 
liver disease) giving sensitivity of about 35% and 90% specificity. 273 
As mentioned above, there is a trade-off between diagnostic sensitivity and specificity. So far 274 
we have compared test performance at 90% specificity. If prevalence of the condition is low, 275 
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it is appropriate to use a high cut-off value to attain high specificity because of the need to 276 
minimise false positives. However, there are clinical situations where high sensitivity is 277 
needed and poor specificity can be tolerated, and detection of continued drinking in patients 278 
with alcoholic cirrhosis may be one of these. If specificity of only 70% can be accepted, then 279 
the sensitivity of GGT for detection of continued drinking in the presence of cirrhosis 280 
increases to about 65% in men (at 133 units/l) and 80% in women (at 85 units/l). However, 281 
even though GGT and AST have some ability to distinguish currently drinking from currently 282 
abstinent patients with alcoholic cirrhosis, it would be inappropriate to place too much 283 
reliance on them. As with patients who do not have liver disease, high GGT should be 284 
considered suggestive of excessive or continuing alcohol use and a finding which warrants 285 
further investigation. 286 
We acknowledge some limitations due to our study design, particularly the existence of 287 
spectrum bias  because of comparison of extremes rather than unselected patients. 288 
Participants were recruited for a case-control genetic association study, so it was important to 289 
select cases with strong evidence of cirrhosis. This limitation should be less of a problem in 290 
the comparison of abstinent and non-abstinent cirrhotic patients, if we assume that alcoholics 291 
are either abstinent or drinking heavily and cannot maintain controlled drinking. Despite 292 
assessment for the absence of past or current symptoms, a few control subjects may have had 293 
some liver damage from alcohol, though probably insignificant given our stringent eligibility 294 
criteria. If liver damage was present in some controls, this would tend to decrease the 295 
difference between cases and controls, and therefore impair test performance. 296 
Another limitation is that test evaluations depend on having a reliable diagnosis. Liver biopsy 297 
is often used as a ‘gold standard’ for cirrhosis but it is invasive, not always justifiable, and 298 
may be subject to sampling error. Clinical symptoms in the presence of high long-term 299 
alcohol intake, and exclusion of alternative causes of cirrhosis, formed the basis for diagnosis 300 
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in our cases; and controls were recruited with similar alcohol intake and absence of 301 
symptoms or history of liver disease. 302 
Finally, we used self-report to assess alcohol intake and abstinence, again with no gold 303 
standard. This has been the method of alcohol use assessment in many studies on alcohol 304 
consumption, both those which have focused on epidemiological associations between 305 
alcohol and health or disease, and those which have evaluated alcohol biomarkers. In general, 306 
self-report is a valid approach to assessment, particularly in a setting in which there are no 307 
negative consequences for a participant who reports ongoing alcohol use, but it may be 308 
subject to bias (22). Accuracy of self-reported alcohol use may vary according to sex, 309 
country, case/control status or other unmeasured factors. However, it is reasonable to assume 310 
that patients with cirrhosis who report continued drinking are giving correct information, 311 
while the group who report abstinence contains some who are drinking. If so, any bias will be 312 
conservative in that test performance will be under-estimated. 313 
 314 
Conclusions   315 
We have documented and compared tests related to liver function in alcoholic cirrhosis, and 316 
shown the best performance for INR and bilirubin. AST and GGT are increased by liver 317 
disease but they may still give useful information on recent alcohol intake in patients with 318 
alcoholic cirrhosis if appropriately higher and sex-specific cut-off values are used. 319 
320 
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Figure 1. Boxplots of AST and GGT results by Case-Control and Abstinent/Non-Abstinent 
status. Boxes show 25th, 50th and 75th centiles, whiskers indicate 95% range. For the legend 
‘Abstinent 60 days’ 1 = Yes (abstinent) and 2 = No (drinking). For each test, values differ 
significantly by both case/control and abstinent drinking status but there is also case/control 
by abstinent/drinking interaction (see Table 2). Abstinent/drinking status has significant 
effects in cases but not in controls. 
  
Figure 2. Comparison of ROC curves for AST and GGT in men and women. Classification 
of Cases as Abstainer for past 60 days versus Non-Abstainer. 
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Table 1. Descriptive data on the 1578 GenomALC Cases and Controls included in the 
analysis. High-risk drinking is defined as equal to or greater than 80 grams of alcohol per day 
for men or 50 grams/day for women, for 10 years or more. 
 Cases (N = 997)  Controls (N = 581) 
 Male Female  Male Female 
Number of subjects 754 243  438 143 
Age (Mean ± SD, in years) 52.6 ± 8.7 50.1 ± 9.6  50.2 ± 10.0 50.3 ± 10.1 
Usual alcohol intake, g/day 211 ± 148 162 ± 118  243 ± 135 197 ± 109 
Years of high-risk drinking 25.3 ± 11.2 19.7 ± 9.8  22.2 ± 9.6 18.4 ± 7.5 
Lifetime alcohol intake, kg 1953 ± 1754 1148 ± 1022  2002 ± 1582 1346 ± 1039 
Number with ascites (ever) 573 (76%) 193 (79%)  0 0 
Number with oesophageal varices (ever) 404 (54%) 126 (52%)  0 0 
Number with encephalopathy (ever) 247 (33%) 89 (37%)  0 0 
Number abstinent for ≥ 60 days 476 (63%) 155 (64%)  13 (3%) 4 (3%) 
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Table 2. Effects of alcoholic cirrhosis (case versus control) and recent drinking (reported abstinence for previous 60 days) on laboratory test results. For 
bilirubin, creatinine, AST, ALT and GGT the significance of differences in means and of the interaction term was assessed on log-transformed data to reduce 
the effects of skewed distributions. To allow for multiple testing, p-values less than 0.0038 (0.05/13) may be considered significant. 
 
    Controls Cases p-values 
    Mean SD N Mean SD N Case-Control Abstinence Interaction 
Haemoglobin,  
(g/l)  
Abstinent 143.6 15.7 16 117.4 23.6 618 1.16 x 10-19 0.944 0.849 Non-Abstinent 142.9 15.7 557 117.7 25.6 362 
             
White cell count 
(cells/l x 10-9)  
Abstinent 7.907 2.549 17 6.267 2.819 616 0.063 0.036 0.029 Non-Abstinent 7.877 2.575 556 8.006 4.413 359 
             
Platelet count 
(cells/l x 10-9)   
Abstinent 251.9 64.3 17 135.8 71.6 613 3.02 x 10-27 0.742 0.480 Non-Abstinent 248.3 81.3 555 146.0 82.8 361 
             
INR 
(ratio)  
Abstinent 1.008 0.243 17 1.402 0.455 595 3.14 x 10-17 0.817 0.495 Non-Abstinent 0.986 0.154 497 1.447 0.508 326 
             
Albumin  
(g/l)  
Abstinent 41.5 4.4 17 35.4 6.9 596 4.01 x 10-18 0.864 0.134 Non-Abstinent 43.0 5.6 545 34.2 7.7 333 
             
Bilirubin  
(µmol/l)  
Abstinent 10.6 8.1 17 50.8 81.6 621 5.20 x 10-31 0.176 0.032 Non-Abstinent 9.3 7.3 553 88.7 130.1 363 
             
Creatinine  
(µmol/l)  
Abstinent 75.1 13.6 17 94.5 67.1 622 0.235 0.0068 0.122 Non-Abstinent 71.9 17.8 558 75.3 39.2 360 
             
ALT  
(units/l)  
Abstinent 56.4 110.7 17 34.5 48.7 620 0.920 0.075 0.030 Non-Abstinent 38.0 34.4 554 45.0 38.8 363 
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    Controls Cases p-values 
    Mean SD N Mean SD N Case-Control Abstinence Interaction 
            
AST  
(units/l)  
Abstinent 48.2 66.2 17 50.1 48.9 606 1.24 x 10-9 3.25 x 10-4 8.71 x 10-4 Non-Abstinent 41.1 33.9 552 83.4 59.5 356 
             
GGT  
(units/l)  
Abstinent 285.5 924.2 17 126.4 171.4 581 1.35 x 10-9 7.39 x 10-7 3.54 x 10-4 Non-Abstinent 113.6 156.8 553 424.0 627.2 348 
           
AST/ALT ratio Abstinent 1.136 0.386 17 1.743 1.029 606 8.18 x 10-13 0.051 0.124  Non-Abstinent 1.184 0.435 547 2.113 0.952 355 
           
AST/platelet ratio Abstinent 0.190 0.225 17 0.524 0.595 596 5.24 x 10-25 0.017 0.061  Non-Abstinent 0.201 0.247 547 0.841 1.017 353 
             
MELD score Abstinent 7.24 1.78 17 13.57 5.95 591 7.42 x 10-25 0.566 0.387   Non-Abstinent 7.05 1.36 490 14.52 6.94 324 
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Table 3. Results of ROC curve analysis; for alcoholic cirrhosis (Cases versus Controls), and for abstinence among patients with alcoholic cirrhosis. To allow 
for multiple testing, p-values less than 0.0038 (0.05/13) may be considered significantly different from chance (i.e. from AUC = 0.500). 
 Cases versus Controls Abstinent Cases versus Drinking Cases 
 N Cases N Controls AUC Std. Error p-value N Drinking N Abstinent AUC Std. Error p-value 
Haemoglobin 982 573 0.802* 0.011 7.63 x 10-88 362 618 0.501 0.019 0.960 
White cell count 977 574 0.644* 0.014 2.05 x 10-21 359 616 0.616 0.019 1.43 x 10-9 
Platelet count 976 573 0.852* 0.010 7.23 x 10-119 361 613 0.528 0.019 0.143 
INR 923 515 0.914 0.008 2.80 x 10-150 326 595 0.522 0.020 0.273 
Bilirubin 986 571 0.875 0.009 2.50 x 10-134 363 621 0.599 0.019 2.40 x 10-7 
Albumin 931 563 0.821* 0.011 1.78 x 10-96 333 596 0.543 0.020 0.031 
AST 964 570 0.685 0.014 8.35 x 10-34 356 606 0.737 0.017 8.85 x 10-35 
ALT 985 572 0.483 0.015 0.275 363 620 0.649 0.018 6.19 x 10-15 
GGT 931 571 0.643 0.014 1.35 x 10-20 348 581 0.771 0.016 2.03 x 10-43 
Creatinine 984 576 0.573 0.014 1.52 x 10-06 360 622 0.643 0.018 6.26 x 10-14 
AST/ALT ratio 963 565 0.774 0.012 2.00 x 10-71 355 606 0.627 0.019 4.61 x 10-11 
AST/platelet ratio 951 565 0.815 0.011 5.73 x 10-94 353 596 0.641 0.018 3.60 x 10-13 
MELD score 917 508 0.914 0.008 7.89 x 10-148 324 591 0.527 0.020 0.173 
∗ Positive status (Case) is associated with lower test result. 
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Table 4. Comparison of selected ROC curve results for all Cases, and for Cases with or without current or 
past ascites. 
 
All With ascites No ascites 
 AUC ± SE AUC ± SE AUC ± SE 
Case versus Control comparison 
INR 0.914 ± 0.008 0.924 ± 0.008 0.884 ± 0.014 
MELD score 0.913 ± 0.008 0.928 ± 0.008 0.865 ± 0.016 
Bilirubin 0.875 ± 0.009 0.881 ± 0.009 0.853 ± 0.015 
Platelet count 0.852 ± 0.010 0.855 ± 0.010 0.842 ± 0.017 
Albumin 0.821 ± 0.011 0.838 ± 0.011 0.762 ± 0.021 
Hemoglobin 0.802 ± 0.011 0.831 ± 0.011 0.703 ± 0.022 
AST 0.685 ± 0.014 0.669 ± 0.015 0.738 ± 0.020 
GGT 0.643 ± 0.014 0.606 ± 0.016 0.762 ± 0.019 
Cases only, Abstinent versus Drinking comparison,  
AST 0.737 ± 0.017 0.717 ± 0.021 0.784 ± 0.031 
GGT 0.771 ± 0.016 0.753 ± 0.020 0.762 ± 0.032 
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Table 5. Details of ROC curve analysis for AST and GGT in distinguishing between Cases with reported abstinence for 60 days and Cases reported as non-
abstinent. 
  AST  GGT  
  Combined Female Male Combined Female Male 
       
AUC (95% CI) 0.737 (0.705 to 0.770) 
0.774 
(0.713 to 0.835) 
0.726 
(0.688 to 0.764) 
0.771 
(0.739 to 0.802) 
0.851 
(0.798 to 0.904) 
0.744 
(0.706 to 0.781) 
Standard Error 0.017 0.031 0.020 0.016 0.027 0.019 
p-value 8.85 x 10-35 2.30 x 10-12 2.31 x 10-24 2.03 x 10-43 2.28 x 10-18 1.92 x 10-27 
       
70% Specificity: Sensitivity   0.67 0.70 0.66 0.69 0.82 0.66 
Cut-off (units/l)  53 53 53 122 85 133 
       
80% Specificity: Sensitivity   0.54 0.59 0.53 0.60 0.74 0.54 
Cut-off (units/l)  63 64 63 168 108 200 
       
85% Specificity: Sensitivity   0.46 0.50 0.45 0.51 0.68 0.49 
Cut-off (units/l)  72 73 72 215 126 232 
       
90% Specificity: Sensitivity   0.37 0.34 0.36 0.46 0.63 0.40 
Cut-off (units/l)  85 87 84 265 138 288 
       
95% Specificity: Sensitivity   0.23 0.22 0.24 0.35 0.54 0.28 
Cut-off (units/l)  105 108 103 363 220 422 
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